Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.47	0.39	1.5	208.38	12.62	0
Revenue Growth (YoY)	283.80%	-73.93%	-99.28%	1551.57%	-	-
Gross Profit	0.47	0.39	1.5	208.38	12.62	0
Selling, General & Admin	29.91	31.09	32.43	37.23	30.63	19.25
Research & Development	32.37	28.59	24.62	46.94	63.42	42.16
Operating Expenses	62.28	59.67	57.05	84.17	94.05	61.41
Operating Income	-61.81	-59.28	-55.55	124.21	-81.43	-61.41
Other Expense / Income	-11.13	-6.94	-1.38	0.05	-0.4	-0.95
Pretax Income	-50.68	-52.34	-54.17	124.16	-81.04	-60.46
Income Tax	0	0	0	1.33	0	0
Net Income	-50.68	-52.34	-54.17	122.83	-81.04	-60.46
Shares Outstanding (Basic)	71	71	70	67	58	39
Shares Outstanding (Diluted)	71	71	70	68	58	39
Shares Change	0.32%	0.22%	3.46%	16.45%	49.04%	59.22%
EPS (Basic)	-0.73	-0.74	-0.77	1.78	-1.39	-1.54
EPS (Diluted)	-0.73	-0.74	-0.77	1.76	-1.39	-1.54
Free Cash Flow	-50.4	-45.82	-56.45	118.43	-51.71	-51.15
Free Cash Flow Per Share	-0.71	-0.65	-0.80	1.75	-0.89	-1.30
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-13052.08%	-15134.60%	-3696.44%	59.61%	-645.40%	-
Profit Margin	-10701.80%	-13362.17%	-3604.66%	58.95%	-642.26%	-
Free Cash Flow Margin	-10643.44%	-11698.19%	-3756.55%	56.83%	-409.85%	-
Effective Tax Rate	-	-	-	1.07%	-	-
EBITDA	-49.08	-50.74	-52.79	124.4	-80.73	-60.21
EBITDA Margin	-10363.78%	-12954.57%	-3512.73%	59.70%	-639.83%	-
Depreciation & Amortization	1.6	1.6	1.38	0.24	0.31	0.26
EBIT	-50.68	-52.34	-54.17	124.16	-81.04	-60.46
EBIT Margin	-10701.80%	-13362.17%	-3604.66%	59.58%	-642.26%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).